Page 57 - 79_02

Nuevas
estrategias
en
terapia
antitumoral
basadas
en
la
inducción
de
la
apoptosis

10. Satyam,
A.;
Hocker.
MD.;
Kane-­-Maguire,
KA.;
Morgan,
AS.;
Villar,
HO.;
Lyttle,
MH.
(1996)

Design,
synthesis,
and
evaluation
of
latent
alkylating
agents
activated
by
glutathione
S-­-
transferase.
J
Med
Chem
39(8),
1736-­-1747.

11. Lyttle,
MH.;
Satyam,
A.;
Hocker,
MD.;
et
al.
(1994)
Glutathione-­-Stransferase
activates
novel

alkylating
agents.
J
Med
Chem
37(10),
1501-­-1507.

12. Thévenin,
AF.;
Zony,
CL.;
Bahnson,
BJ.;
Colman,
RF.
(2011)
GSTpi
modulates
JNK
activity

through
a
direct
interaction
with
JNK
substrate,
ATF2.
Protein
Sci
20(5),
834-­-848.

13. Vergotea,
I.;
Finklerb,
N.;
Del
Campoc.
J.
et
al.
(2009)
Phase
3
randomised
study
of

canfosfamide
(Telcyta®,
TLK286)
versus
pegylated
liposomal
doxorubicin
or
topotecan

as
third-­-line
therapy
in
patients
with
platinum-­-refractory
or
–resistant
ovarian
cancer.

Eur
J
Cancer
45,
2324-­-2332.

14. Turella,
P.;
Filomeni,
G.;
Dupuis,
ML.
et
al.
(2006)
A
strong
glutathione
S-­-transferase

inhibitor
overcomes
the
p-­-glycoproteinmediated
resistance
in
tumour
cells.
6-­-(7-­-nitro-­-
2,1,3-­-benzoxadiazol-­-4-­-ylthio)hexanol
(NBDHEX)
triggers
a
caspasedependent
apoptosis

in
MDR1-­-expressing
leukemia
cells.
J
Biol
Chem
281,
23725-­-23732.

15. Filomeni,
G.;
Turella,
P.;
Dupuis,
ML.
et
al.
(2008)
6-­-(7-­-nitro-­-2,
1,
3-­-benzoxadiazol-­-4-­-
ylthio)hexanol,
a
specific
glutathione
Stransferase
inhibitor,
overcomes
the
multidrug

resistance
(MDR)-­-associated
protein
1-­-mediated
MDR
in
small
cell
lung
cancer.
Mol

Cancer
Ther
7,
371-­-379.

16. Pellizzari
Tregno,
F.;
Sau,
A.;
Pezzola,
S.
et
al.
(2009)
In
vitro
and
in
vivo
efficacy
of
6-­-(7-­-
nitro-­-2,
1,
3-­-benzoxadiazol-­-4-­-ylthio)hexanol
(NBDHEX)
on
human
melanoma.
Eur
J

Cancer
45,
2606-­-2617.

17. Tentori,
L.;
Dorio,
AS.;
Mazzon,
E.;
Muzi,
A.;
Sau,
A.;
Cuzzocrea,
S.
et
al.
(2011)
The

glutathione
transferase
inhibitor
6-­-(7-­-nitro-­-2,1,3-­-benzoxadiazol-­-4-­-ylthio)hexanol

(NBDHEX)
increases
temozolomide
efficacy
against
malignant
melanoma.
Eur
J
Cancer
45,

1219-­-1230.

18. Huang,
S.;
Shu,
L.;
Easton,
J.
et
al.
(2004)
Inhibition
of
Mammalian
Target
of
Rapamycin

Activates
Apoptosis
Signal-­-regulating
Kinase
1
Signaling
by
Suppressing
Protein

Phosphatase
5
Activity.
J
Biol
Chem
279(35),
36490-­-36496.

19. Temkin,
SM.;
Yamada,
SD.;
Fleming,
GF.
(2010)
A
phase
I
study
of
weekly
temsirolimus

and
topotecan
in
the
treatment
of
advanced
and/or
recurrent
gynecologic
malignancies.

Gynecol
Oncol
117,
473-­-476.

20. Yap,
TA.;
Garrett1,
MD.;
Walton,
MI.;
Raynaud,
F.;
De
Bono,
JS.;
Workman,
P.
(2008)

Targeting
the
PI3K–AKT–mTOR
pathway:
progress,
pitfalls,
and
promises.
Curr
Opin
in

Pharmacol
8,
393-­-412.

21. Strimpakos,
AS.;
Karapanagiotou,
EM.;
Saif,
MW.;
Syrigos,
KN.
(2009)
The
role
of
mTOR
in

the
management
of
solid
tumors:
An
overview.
Cancer
Treat
Rev;
35:148-­-159.

22. Ciardiello
F.
(2005)
Epidermal
growth
factor
receptor
inhibitors
in
cancer
treatment.

Future
Oncol
1(2),
221-­-234.

23. Salomon,
DS.;
Brandt,
R.;
Ciardiello,
F.
et
al.
(1995)
Epidermal
growth
factorrelated

peptides
and
their
receptors
in
human
malignancies.
Crit
Rev
Oncol/Hematol
19,
183-­-232.

24. Dummer
Meira,
D.;
Nóbrega,
I.;
De
Almeida,
VH.;
Mororo,
JS.;
Cardoso,
AM.;
Silva,
R.
(2009)

Different
antiproliferative
effects
of
matuzumab
and
cetuximab
in
A431
cells
are

associated
with
persistent
activity
of
the
MAPK
pathway.
Eur
J
Cancer
45,
1265-­-1273.

25. Oh,
IJ.;
Jung-­-Ban,
H.;
Kim,
KS.;
Kim,
YC.
(2012)
Retreatment
of
gefitinib
in
patients
with

non-­-small-­-cell
lung
cancer
who
previously
controlled
to
gefitinib:
A
single-­-arm,
open-­-label,

phase
II
study.
Lung
Cancer
77,
121-­-127.

26. Chang,
SC.;
Chang,
CY.;
Chang,
SJ.;
Yuan,
MK.;
Lai,
YC.;
Liu,
YC.
(2013)
Gefitinib-­-Related

Interstitial
Lung
Disease
in
Taiwanese
Patients
With
Non–Small-­-Cell
Lung
Cancer.
Clin

Lung
Cancer
14(1),
55-­-61.

227